Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (formerly Xcyte Therapies, Inc.)
Reporting Period: Quarterly period ended June 30, 2006
Business Overview: A development-stage biopharmaceutical company focused on discovering and developing mechanism-targeted drugs for cancer and other serious disorders. The company operates research facilities in Short Hills, NJ; Dundee, Scotland; and Cambridge, England.
Key Corporate Event: On March 27, 2006, the company completed a reverse acquisition of Cyclacel Limited (formerly a subsidiary of Cyclacel Group plc). The transaction was accounted for as a reverse merger, with Cyclacel Limited deemed the accounting acquirer. The company also sold its T-cell expansion technology ("Xcellerate Process") to Invitrogen for $5 million in March 2006.
Key Financial Metrics
| Metric ($000s) | Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 |
|---|---|---|
| Total Revenues | 187 | 127 |
| Net Loss | (18,291) | (10,433) |
| Net Loss per Share (Basic/Diluted) | $ (1.90) | $ (2.11) |
| Cash and Cash Equivalents (End of Period) | 63,101 | 5,988 |
| Short-term Investments | 1,886 | 6,600 (approx. derived from prior period context) |
| Total Assets | 72,667 | 19,071 (Dec 31, 2005) |
| Total Liabilities | 8,421 | 14,952 (Dec 31, 2005) |
| Accumulated Deficit | (127,309) | (109,018) (Dec 31, 2005) |
Operating Expenses: Total operating expenses for the six months ended June 30, 2006, were $20.1 million, driven primarily by Research and Development (R&D) of $13.1 million and General and Administrative (G&A) of $6.9 million. Stock-based compensation accounted for $9.1 million of these expenses.
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $3.1 million (Dec 31, 2005) to $63.1 million (June 30, 2006). This was primarily due to $42.6 million in net proceeds from a private placement in April 2006 and $21.6 million in cash/investments assumed from the reverse merger.
- Revenue Growth: Total revenue increased to $187,000 for the six months ended June 30, 2006, compared to $127,000 in the prior year period. This includes collaboration/research revenue ($125,000) and grant revenue ($62,000).
- Expense Increase: Net loss widened to $18.3 million from $10.4 million in the prior year period. The increase is largely attributable to a $5.1 million increase in stock-based compensation expense due to the adoption of SFAS 123R and accelerated vesting of options related to the merger.
- Balance Sheet Restructuring: The company recorded $2.5 million in accrued restructuring charges related to the abandonment of leasehold improvements in Seattle and Bothell facilities. Goodwill of $2.7 million was recognized from the reverse merger.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management anticipates that current cash, cash equivalents, and marketable securities ($65.0 million total) will be sufficient to fund operations through the second quarter of 2008. However, the company expects to continue incurring substantial operating losses and will require substantial additional capital to complete clinical trials and commercialize drug candidates.
Management Commentary:
- Clinical Pipeline: The company is advancing three lead candidates: seliciclib (CDK inhibitor), sapacitabine (nucleoside analogue), and CYC116 (Aurora kinase inhibitor). A Phase IIb trial for seliciclib in non-small cell lung cancer began in June 2006.
- Asset Sale: The sale of the Xcellerate Process to Invitrogen for $5 million (subject to a potential $1 million refund) divested the company of its T-cell expansion technology to focus on small molecule therapeutics.
Risks and Contingencies:
- Regulatory Risk: No products have been approved for commercial sale. Success depends on FDA and other regulatory approvals, which are uncertain.
- Financial Risk: The company has an accumulated deficit of $127.3 million and relies on equity financing. Failure to raise additional funds could force delays or termination of clinical trials.
- Tax Contingency: The company is under audit by the State of Washington regarding a high-technology sales tax deferral program. A potential liability of $270,000 to $1 million exists; $270,000 has been accrued.
- Derivative Liability: A $1.6 million derivative liability exists related to a dividend make-whole feature on convertible preferred stock, which fluctuates with fair value.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $65 million cash balance to fund operations through Q2 2008 given the high burn rate ($18.3 million loss in six months).
- Stock-Based Compensation: Review the impact of SFAS 123R adoption and the $9.1 million non-cash charge on future earnings and dilution.
- Restructuring Liability: Monitor the $2.5 million accrued liability for the Bothell facility lease and the potential for additional accretion or sublease income adjustments.
- Tax Audit Status: Track the resolution of the Washington State sales tax audit, which could result in an additional liability up to $1 million.
- Clinical Milestones: Confirm progress and results of the Phase IIb seliciclib trial and the Phase I sapacitabine trial, as these are critical for future valuation and partnership opportunities.
- Derivative Valuation: Assess the volatility of the $1.6 million derivative liability and its potential impact on future net income.